FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1926565992> ?p ?o ?g. }

• W1926565992 abstract "Retrospective studies have demonstrated high response rates among patients with advanced pancreatic neuroendocrine tumors (PNETs) treated with capecitabine and temozolamide (CapTem), while responses are infrequently seen among non-PNETs. The objective of the study was to describe progression free survival (PFS) among neuroendocrine tumor (NET) patients treated with CapTem, and to identify factors associated with better activity.Patients who were referred to one of five provincial cancer treatment centers between 2009 and 2013 for advanced NETs and initiated CapTem were included. Patients received Cap 1,500 mg/m(2) on days 1-14 and TMZ 200 mg/m(2) on days 10-14 every 28 days. Their characteristics and outcomes were retrospectively analyzed.In our cohort, 29 patients (16 males) with a median age of 59 (range 26-76) received palliative CapTem, 15 of them as first-line chemotherapy. Primary tumors included pancreas (48.3%), small bowel (20.7%), lung (10.3%), unknown (10.3%), rectum (6.9%) and appendix (3.4%). Median number of cycles was three. Fifteen patients (51.7%) received CapTem as first-line chemotherapy and 14 (48.3%) as subsequent lines. Median PFS for the entire cohort was 4.7 months. PNETs had a median PFS of 4.9 months compared to 2.8 months for non-PNETs (P=0.178). Patients with PNETs who received CapTem in the first-line setting had a median PFS of 15.9 months as compared to only 3.1 months for the remainder [P=0.047, hazard ratios (HR) 0.342]. Patients with Ki67 above 5% and ≤5% had median PFS of 4.0 and 4.7 months, respectively (P=0.260).CapTem showed good activity among PNETs, but its broader role in the treatment of carcinoid tumors remains unclear." @default.
• W1926565992 created "2016-06-24" @default.
• W1926565992 creator A5051782879 @default.
• W1926565992 creator A5053138163 @default.
• W1926565992 creator A5066204572 @default.
• W1926565992 creator A5075109756 @default.
• W1926565992 creator A5089913686 @default.
• W1926565992 date "2014-08-01" @default.
• W1926565992 modified "2023-10-12" @default.
• W1926565992 title "Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs." @default.
• W1926565992 cites W1839519286 @default.
• W1926565992 cites W1861898234 @default.
• W1926565992 cites W1993232904 @default.
• W1926565992 cites W2053103602 @default.
• W1926565992 cites W2081457024 @default.
• W1926565992 cites W2083682712 @default.
• W1926565992 cites W2090232354 @default.
• W1926565992 cites W2115686439 @default.
• W1926565992 cites W2128879260 @default.
• W1926565992 cites W2130735070 @default.
• W1926565992 cites W2135657152 @default.
• W1926565992 cites W2153217491 @default.
• W1926565992 cites W2158474413 @default.
• W1926565992 cites W2162830031 @default.
• W1926565992 cites W2263248967 @default.
• W1926565992 cites W2339290868 @default.
• W1926565992 doi "https://doi.org/10.3978/j.issn.2078-6891.2014.019" @default.
• W1926565992 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4110496" @default.
• W1926565992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25083296" @default.
• W1926565992 hasPublicationYear "2014" @default.
• W1926565992 type Work @default.
• W1926565992 sameAs 1926565992 @default.
• W1926565992 citedByCount "22" @default.
• W1926565992 countsByYear W19265659922014 @default.
• W1926565992 countsByYear W19265659922016 @default.
• W1926565992 countsByYear W19265659922017 @default.
• W1926565992 countsByYear W19265659922018 @default.
• W1926565992 countsByYear W19265659922019 @default.
• W1926565992 countsByYear W19265659922020 @default.
• W1926565992 countsByYear W19265659922021 @default.
• W1926565992 countsByYear W19265659922022 @default.
• W1926565992 crossrefType "journal-article" @default.
• W1926565992 hasAuthorship W1926565992A5051782879 @default.
• W1926565992 hasAuthorship W1926565992A5053138163 @default.
• W1926565992 hasAuthorship W1926565992A5066204572 @default.
• W1926565992 hasAuthorship W1926565992A5075109756 @default.
• W1926565992 hasAuthorship W1926565992A5089913686 @default.
• W1926565992 hasConcept C121608353 @default.
• W1926565992 hasConcept C126322002 @default.
• W1926565992 hasConcept C143998085 @default.
• W1926565992 hasConcept C167135981 @default.
• W1926565992 hasConcept C207103383 @default.
• W1926565992 hasConcept C2776694085 @default.
• W1926565992 hasConcept C2777909004 @default.
• W1926565992 hasConcept C2778764654 @default.
• W1926565992 hasConcept C2779066768 @default.
• W1926565992 hasConcept C2780739268 @default.
• W1926565992 hasConcept C2781074409 @default.
• W1926565992 hasConcept C44249647 @default.
• W1926565992 hasConcept C526805850 @default.
• W1926565992 hasConcept C71924100 @default.
• W1926565992 hasConcept C72563966 @default.
• W1926565992 hasConcept C90924648 @default.
• W1926565992 hasConceptScore W1926565992C121608353 @default.
• W1926565992 hasConceptScore W1926565992C126322002 @default.
• W1926565992 hasConceptScore W1926565992C143998085 @default.
• W1926565992 hasConceptScore W1926565992C167135981 @default.
• W1926565992 hasConceptScore W1926565992C207103383 @default.
• W1926565992 hasConceptScore W1926565992C2776694085 @default.
• W1926565992 hasConceptScore W1926565992C2777909004 @default.
• W1926565992 hasConceptScore W1926565992C2778764654 @default.
• W1926565992 hasConceptScore W1926565992C2779066768 @default.
• W1926565992 hasConceptScore W1926565992C2780739268 @default.
• W1926565992 hasConceptScore W1926565992C2781074409 @default.
• W1926565992 hasConceptScore W1926565992C44249647 @default.
• W1926565992 hasConceptScore W1926565992C526805850 @default.
• W1926565992 hasConceptScore W1926565992C71924100 @default.
• W1926565992 hasConceptScore W1926565992C72563966 @default.
• W1926565992 hasConceptScore W1926565992C90924648 @default.
• W1926565992 hasLocation W19265659921 @default.
• W1926565992 hasOpenAccess W1926565992 @default.
• W1926565992 hasPrimaryLocation W19265659921 @default.
• W1926565992 hasRelatedWork W1596193789 @default.
• W1926565992 hasRelatedWork W1839519286 @default.
• W1926565992 hasRelatedWork W2008997722 @default.
• W1926565992 hasRelatedWork W2090232354 @default.
• W1926565992 hasRelatedWork W2115686439 @default.
• W1926565992 hasRelatedWork W2118672029 @default.
• W1926565992 hasRelatedWork W2128879260 @default.
• W1926565992 hasRelatedWork W2130735070 @default.
• W1926565992 hasRelatedWork W2135049144 @default.
• W1926565992 hasRelatedWork W2135657152 @default.
• W1926565992 hasRelatedWork W2137142564 @default.
• W1926565992 hasRelatedWork W2152154338 @default.
• W1926565992 hasRelatedWork W2158474413 @default.
• W1926565992 hasRelatedWork W2161676563 @default.
• W1926565992 hasRelatedWork W2162830031 @default.
• W1926565992 hasRelatedWork W2229261843 @default.
• W1926565992 hasRelatedWork W2339290868 @default.
• W1926565992 hasRelatedWork W2512663019 @default.

• next